-DOCSTART- -X- O
Human -X- _ O
metapneumovirus -X- _ O
( -X- _ O
hMPV -X- _ O
) -X- _ O
infection -X- _ O
causes -X- _ O
acute -X- _ O
respiratory -X- _ O
tract -X- _ O
infections -X- _ O
( -X- _ O
RTI -X- _ O
) -X- _ O
which -X- _ O
can -X- _ O
result -X- _ O
in -X- _ O
hospitalization -X- _ O
of -X- _ O
both -X- _ O
children -X- _ O
and -X- _ O
adults. -X- _ O
To -X- _ O
date -X- _ O
, -X- _ O
no -X- _ O
antiviral -X- _ O
or -X- _ O
vaccine -X- _ O
is -X- _ O
available -X- _ O
for -X- _ O
this -X- _ O
common -X- _ O
viral -X- _ O
infection. -X- _ O
Immunomodulators -X- _ O
could -X- _ O
represent -X- _ O
an -X- _ O
interesting -X- _ O
strategy -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
severe -X- _ O
viral -X- _ O
infection. -X- _ O
Recently -X- _ O
, -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
protease-activated -X- _ B-Intervention
receptors -X- _ I-Intervention
( -X- _ I-Intervention
PAR -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ O
inflammation -X- _ O
, -X- _ O
coagulation -X- _ O
and -X- _ O
infection -X- _ O
processes -X- _ O
has -X- _ O
been -X- _ O
of -X- _ O
growing -X- _ O
interest. -X- _ O
Herein -X- _ O
, -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
a -X- _ O
PAR1 -X- _ B-Intervention
agonist -X- _ I-Intervention
and -X- _ I-Intervention
a -X- _ I-Intervention
PAR1 -X- _ I-Intervention
antagonist -X- _ I-Intervention
on -X- _ O
hMPV -X- _ B-Patient
infection -X- _ I-Patient
were -X- _ I-Patient
investigated -X- _ I-Patient
in -X- _ I-Patient
BALB -X- _ I-Patient
/ -X- _ I-Patient
c -X- _ I-Patient
mice. -X- _ I-Patient
Intranasal -X- _ B-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
PAR1 -X- _ I-Outcome
agonist -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
increased -X- _ I-Outcome
weight -X- _ I-Outcome
loss -X- _ I-Outcome
and -X- _ I-Outcome
mortality -X- _ I-Outcome
of -X- _ I-Outcome
infected -X- _ I-Outcome
mice. -X- _ I-Outcome
Conversely -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
PAR1 -X- _ I-Outcome
antagonist -X- _ I-Outcome
was -X- _ I-Outcome
beneficial -X- _ I-Outcome
to -X- _ I-Outcome
hMPV -X- _ I-Outcome
infection -X- _ I-Outcome
by -X- _ I-Outcome
decreasing -X- _ I-Outcome
weight -X- _ I-Outcome
loss -X- _ I-Outcome
and -X- _ I-Outcome
clinical -X- _ I-Outcome
signs -X- _ I-Outcome
and -X- _ I-Outcome
by -X- _ I-Outcome
significantly -X- _ I-Outcome
reducing -X- _ I-Outcome
pulmonary -X- _ I-Outcome
inflammation -X- _ I-Outcome
, -X- _ I-Outcome
pro- -X- _ I-Outcome
inflammatory -X- _ I-Outcome
cytokine -X- _ I-Outcome
levels -X- _ I-Outcome
( -X- _ I-Outcome
including -X- _ I-Outcome
IL-6 -X- _ I-Outcome
, -X- _ I-Outcome
KC -X- _ I-Outcome
and -X- _ I-Outcome
MCP-1 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
recruitment -X- _ I-Outcome
of -X- _ I-Outcome
immune -X- _ I-Outcome
cells -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
lungs. -X- _ I-Outcome
In -X- _ I-Outcome
addition -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
pulmonary -X- _ I-Outcome
viral -X- _ I-Outcome
titers -X- _ I-Outcome
was -X- _ I-Outcome
also -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
lungs -X- _ I-Outcome
of -X- _ I-Outcome
PAR1 -X- _ I-Outcome
antagonist-treated -X- _ I-Outcome
mice. -X- _ I-Outcome
Despite -X- _ I-Outcome
no -X- _ I-Outcome
apparent -X- _ I-Outcome
direct -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
virus -X- _ I-Outcome
replication -X- _ I-Outcome
during -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
experiments -X- _ I-Outcome
, -X- _ I-Outcome
an -X- _ I-Outcome
important -X- _ I-Outcome
role -X- _ I-Outcome
for -X- _ I-Outcome
PAR1 -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
regulation -X- _ I-Outcome
of -X- _ I-Outcome
furin -X- _ I-Outcome
expression -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
lungs -X- _ I-Outcome
was -X- _ I-Outcome
shown -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
first -X- _ I-Outcome
time. -X- _ I-Outcome
Further -X- _ O
experiments -X- _ O
indicated -X- _ O
that -X- _ O
the -X- _ O
hMPV -X- _ O
fusion -X- _ O
protein -X- _ O
can -X- _ O
be -X- _ O
cleaved -X- _ O
by -X- _ O
furin -X- _ O
thus -X- _ O
suggesting -X- _ O
that -X- _ O
PAR1 -X- _ O
could -X- _ O
have -X- _ O
an -X- _ O
effect -X- _ O
on -X- _ O
viral -X- _ O
infectivity -X- _ O
in -X- _ O
addition -X- _ O
to -X- _ O
its -X- _ O
immunomodulatory -X- _ O
properties. -X- _ O
Thus -X- _ O
, -X- _ O
inhibition -X- _ O
of -X- _ O
PAR1 -X- _ O
by -X- _ O
selected -X- _ O
antagonists -X- _ O
could -X- _ O
represent -X- _ O
an -X- _ O
interesting -X- _ O
strategy -X- _ O
for -X- _ O
decreasing -X- _ O
the -X- _ O
severity -X- _ O
of -X- _ O
paramyxovirus -X- _ O
infections -X- _ O
. -X- _ O

